Drug Profile
Ravidasvir plus sofosbuvir - Drugs for Neglected Diseases initiative/Pharco Pharmaceuticals
Latest Information Update: 22 Feb 2022
Price :
$50
*
At a glance
- Originator Drugs for Neglected Diseases Initiative Foundation
- Class Benzimidazoles; Carbamates; Naphthalenes; Phosphoric acid esters; Pyrimidine nucleotides; Pyrrolidines; Small molecules
- Mechanism of Action Hepatitis C virus NS 5 protein inhibitors; Hepatitis C virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Hepatitis C
Most Recent Events
- 31 Dec 2021 Phase II/III development is ongoing in Thailand and Malaysia (Drugs for Neglected Diseases Initiative pipeline, December 2021)
- 25 Nov 2019 DNDi and Pharco Pharmaceuticals intend to pursue registration for Hepatitis C (PO) in Malaysia in 2020
- 12 Apr 2018 Efficacy data from a STORM-C-1 phase II/III trial in indication) presented at the International Liver Conference (ILC-2020)